Mutation News and Research

RSS

New antibody targets cancer-causing HER2 mutations

For some proteins, a single mutation, or change in its DNA instructions, is all it takes to tip the balance between functioning normally and causing cancer.

22 Oct 2024

Novel antibodies show promise for tumor targeting and RAD51 inhibition

A new research paper was published in Oncotarget's Volume 15 on October 1, 2024, entitled, "Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition."

21 Oct 2024

Scientists map the genetic landscape of drug resistance in cancers

All cancer mutations that cause drug resistance fall into one of four categories. New research has detailed each type, helping to uncover targets for drug development and identify potential effective second-line therapies.

18 Oct 2024

Researchers identify protein linked to cardiovascular health in progeria

A new University of Maryland-led discovery could spur the development of new and improved treatments for Hutchinson-Gilford progeria syndrome (HGPS), a rare genetic disorder with no known cure that causes accelerated aging in children.

18 Oct 2024

Study reveals gender differences in Rett syndrome progression

A new UC Davis MIND Institute study offers critical insights into Rett syndrome, a rare genetic condition that affects mostly girls.

17 Oct 2024

Adenine base editors show potential to correct X-CGD-causing mutations

A collaborative effort between investigators at the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham healthcare system, demonstrates the potential of precise genome editing technologies, called adenine base editors, to correct disease-causing mutations in stem cells from patients with X-linked chronic granulomatous disease (X-CGD), a rare genetic disorder characterized by high susceptibility to infections.

16 Oct 2024

Study reveals genetic factors affecting birth sex ratios

Each year, roughly the same numbers of boys and girls are born.

16 Oct 2024

New drug targets identified for retinitis pigmentosa therapies

An international team of researchers has identified new drug targets for therapies that could benefit patients with different forms of retinitis pigmentosa and other inherited retinal diseases.

16 Oct 2024

Structural biology uncovers the molecular basis of b1 vitamin transport and deficiency

Vitamin B1, also known as thiamine, is essential for the survival of our cells. The human body can't produce it, but we can maintain healthy levels of this vitamin by eating foods like salmon, legumes, and brown rice.

16 Oct 2024

Gene editing restores treatment sensitivity in melanoma

In a potential advance for melanoma patients, researchers at ChristianaCare’s Gene Editing Institute have used CRISPR gene editing tools to disable a gene mutation often seen in aggressive forms of this dangerous skin cancer that renders promising treatments ineffective.

16 Oct 2024

SU2C announces grants to support cutting-edge research in a variety of cancers

Stand Up To Cancer (SU2C) today announced grants to several teams of leading cancer investigators in support of cutting-edge research in a variety of cancers including head and neck, pediatric, pancreatic, breast, rectal and gastro-esophageal cancers, as well as research focused on how the microbiome communicates with the immune system.

15 Oct 2024

A novel approach to understanding protein compartmentalization

In physics, a system composed of two substances can be modeled in accordance with classical mixture theory, which considers the fraction corresponding to each constituent and the interactions among constituents. Examples include the coexistence of high- and low-density phases in supercooled water and the coexistence of metal puddles in an insulating matrix in the Mott metal-insulator transition.

14 Oct 2024

Evaluating allogeneic transplant for TP53 mutated acute myeloid leukemia

A new editorial was published in Oncotarget's Volume 15 on October 1, 2024, entitled, "Transplant or no transplant for TP53 mutated AML."

12 Oct 2024

Grant supports gene-editing research for rare metabolic diseases

A $14M grant will fund research on gene-editing therapies for rare metabolic diseases at the Perelman School of Medicine at the University of Pennsylvania (Penn) and Children's Hospital of Philadelphia (CHOP).

10 Oct 2024

Novel gene therapy holds potential in treating patients with epilepsy

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.

9 Oct 2024

Novel compounds show promise in fighting COVID-19

New research from The Wistar Institute's Salvino lab -; led by professor Joseph Salvino, Ph.D. -; has identified a novel series of SARS-CoV-2 Mpro inhibitors that may lead to potential new COVID-19 treatments that, according to preclinical testing, effectively inhibits COVID-19 and synergizes with existing anti-COVID therapies.

8 Oct 2024

Clonal competition assays reveal tumor cell resistance mechanisms

All cells within the same cancer are not the same. They all have genetic errors that turn them into tumor cells, but these errors are not identical.

8 Oct 2024

New insights into how stress affects pancreatic cells and diabetes risk

The cells in your pancreas, like people, can only handle so much stress before they start to break down. Certain stressors, such as inflammation and high blood sugar, contribute to the development of type 2 diabetes by overwhelming these cells.

8 Oct 2024

Liver X receptor beta offers new hope in treating depression and anxiety

Liver X receptor beta (LXRβ) shows potential in reducing depression and anxiety by improving neurogenesis, reducing neuroinflammation, and enhancing cognitive and emotional function. More research on LXR agonists could reveal new treatments for mental health disorders.

8 Oct 2024

When CDK12/13 stalls, healthy prostate cells take a malignant turn

CDK12 is established as a tumor suppressor in prostate cancer, with its loss driving aggressive disease and creating vulnerabilities for targeted therapies.

7 Oct 2024